- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2022 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Cardiology
The Endocrinology Network® Cardiology clinical resource center is a hub of news related to cardiovascular health that is relevant to clinicians interested in endocrinology. This page will host relevant content about cardiology and cardiovascular disease including guideline updates, new studies and breakthroughs, and clinical perspectives for practicing clinicians.
Diabetic Ketoacidosis Raises Risk of In-Hospital Mortality, Hospital Readmission in Heart Failure
May 17, 2022
Diabetic ketoacidosis increased the likelihood of in-hospital mortality by 61%, the likelihood of major adverse cardiovascular events by 56%, and a likelihood of 30-day readmission by 12% among patients hospitalized with heart failure in the US.
Reducing Sedentary Time By An Hour Per Day Can Provide Health Benefits in Metabolic Syndrome
May 05, 2022
A 3-month trial found reducing sedentary time by just an hour per day was enough to produce statistically significant changes in biomarkers for cardiovascular risk among patients with metabolic syndrome.
SGLT2 Inhibitor, GLP-1 Receptor Agonist Prescribing Increased Sharply Since 2015
May 02, 2022
New data suggests the number of prescriptions for SGLT2 inhibitors in the US has doubled since 2015 with prescriptions for GLP-1 receptor agonists tripling during the same time period.
Calcium Supplementation Could Increase Risk of Death in Older Adults with Cardiovascular Disease
April 28, 2022
An analysis of data from a Cleveland Clinic database indicates calcium supplementation in older adults with aortic stenosis was linked to an increased risk of mortality and worsening aortic stenosis.
Initial eGFR Dips Common with SGLT2 Inhibitors, Not Typically Associated with Negative Outcomes
April 25, 2022
An analysis of the DAPA-HF trial provides insight into the occurrence of eGFR dips in the first 14 days following initiation of therapy with an SGLT2 inhibitor and their association with long-term outcomes.
Cognitive Impairment Tied to Increased Cardiovascular Disease Risk in Type 2 Diabetes
April 21, 2022
Analysis of the REWIND trial indicates cognitive impairment among patients with diabetes was associated with a 1.6 times greater risk of major adverse cardiovascular events and a 1.8 times greater risk of stroke or mortality.
Study Quantifies Life-Years Added from Meeting Treatment Goals in Type 2 Diabetes
April 18, 2022
A microsimulation model provides insight into potential years of life expectancy gained by meeting recommended treatment goals for HbA1c, LDL-C, BMI, and blood pressure among adult patients with type 2 diabetes.
Finerenone Reduces CV Risk in T2D and CKD, Regardless of ASCVD History
April 07, 2022
A prespecified analysis of FIDELITY details the effects of finerenone against placebo therapy for reducing the risk of cardiovascular events based on history of ASCVD among patients with type 2 diabetes and chronic kidney disease.
Comparing Initiation of SGLT2i/GLP-1 RA Combination Therapy to Monotherapy
April 06, 2022
A study from Intermountain Healthcare provides insight into the tolerability and clinical impact and tolerability of initiating combination therapy with both SGLT2 inhibitors and GLP-1 RAs compared against monotherapy with either agent.
Infertility Treatments Could Raise Risk of Acute Kidney Injury, Heart Rhythm Disorders
February 25, 2022
New research suggests pregnancies conceived with assisted reproductive technology were associated with a more than doubling in risk for acute kidney injury.